Aimmune Therapeutics, Inc. (NASDAQ:AIMT) insider Douglas T. Sheehy sold 1,648 shares of the business’s stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $37.33, for a total value of $61,519.84. Following the completion of the sale, the insider now owns 1,648 shares of the company’s stock, valued at approximately $61,519.84. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Shares of Aimmune Therapeutics, Inc. (NASDAQ AIMT) opened at $38.31 on Wednesday. The firm has a market capitalization of $1,950.00 and a P/E ratio of -16.37. Aimmune Therapeutics, Inc. has a 12-month low of $15.97 and a 12-month high of $40.00.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.63) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.72) by $0.09. equities analysts forecast that Aimmune Therapeutics, Inc. will post -2.51 earnings per share for the current year.

AIMT has been the subject of a number of recent research reports. Cantor Fitzgerald initiated coverage on Aimmune Therapeutics in a research report on Tuesday, December 12th. They issued an “overweight” rating and a $55.00 target price for the company. BidaskClub downgraded Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, January 4th. Zacks Investment Research upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, October 16th. Roth Capital initiated coverage on Aimmune Therapeutics in a research report on Monday, November 20th. They issued a “buy” rating and a $60.00 target price for the company. Finally, Wedbush restated an “outperform” rating and issued a $70.00 target price (up previously from $42.00) on shares of Aimmune Therapeutics in a research report on Monday, October 23rd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. Aimmune Therapeutics presently has an average rating of “Hold” and a consensus price target of $55.43.

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in Aimmune Therapeutics by 12.6% in the 2nd quarter. Vanguard Group Inc. now owns 2,476,836 shares of the biotechnology company’s stock worth $50,923,000 after purchasing an additional 276,978 shares during the period. Palo Alto Investors LLC increased its stake in Aimmune Therapeutics by 9.9% in the 2nd quarter. Palo Alto Investors LLC now owns 1,289,719 shares of the biotechnology company’s stock worth $26,517,000 after purchasing an additional 116,221 shares during the period. Point72 Asset Management L.P. increased its stake in Aimmune Therapeutics by 10.2% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,098,087 shares of the biotechnology company’s stock worth $27,222,000 after purchasing an additional 101,855 shares during the period. State Street Corp increased its stake in Aimmune Therapeutics by 26.6% in the 2nd quarter. State Street Corp now owns 1,087,320 shares of the biotechnology company’s stock worth $22,351,000 after purchasing an additional 228,429 shares during the period. Finally, Citadel Advisors LLC increased its stake in Aimmune Therapeutics by 3,092.5% in the 3rd quarter. Citadel Advisors LLC now owns 559,641 shares of the biotechnology company’s stock worth $13,873,000 after purchasing an additional 542,111 shares during the period. 73.34% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Douglas T. Sheehy Sells 1,648 Shares of Aimmune Therapeutics, Inc. (AIMT) Stock” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/01/10/douglas-t-sheehy-sells-1648-shares-of-aimmune-therapeutics-inc-aimt-stock.html.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Insider Buying and Selling by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.